AbbVie (ABBV) Q2 2023: Growth Platform Lifts Guidance by $1.4B as Humira Erosion Stabilizes
AbbVie’s growth platform outpaces expectations, offsetting Humira biosimilar headwinds and driving a $1.4B guidance upgrade. Robust execution in immunology, neuroscience, and aesthetics underpins confidence in a 2025 growth inflection. Management signals durable momentum beyond the Humira loss-of-exclusivity trough, with pipeline and commercial leverage extending visibility into the next decade.
Summary
- Growth Platform Acceleration: Ex-Humira franchises delivered high single-digit growth, driving the majority of guidance raise.
- Immunology and Neuroscience Outperformance: Skyrizi, RINVOQ, and migraine assets continue to capture share and expand indications.
- Long-Term Visibility Strengthens: Management projects high single-digit growth resumption post-2024, with pipeline and M&A optionality supporting outlook.
Business Overview
AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics. The company generates revenue through a portfolio of branded prescription medicines, led historically by Humira, an anti-inflammatory biologic, but increasingly from next-generation therapies such as Skyrizi (IL-23 inhibitor for autoimmune diseases), RINVOQ (JAK inhibitor), neuroscience treatments (e.g., Vraylar, Qulipta), and its Allergan Aesthetics franchise (Botox, Juvederm). Major segments include Immunology, Oncology, Neuroscience, and Aesthetics, with Immunology representing the largest share of total revenue.
Performance Analysis
AbbVie’s Q2 2023 results reflect a decisive pivot from Humira dependence to a diversified growth engine. Total net revenues reached nearly $13.9B, with the growth platform—defined as all products excluding Humira—delivering operational revenue growth of nearly 8%. Immunology led the charge, as Skyrizi and RINVOQ both posted sales growth above 50% YoY, now collectively approved across 10 indications and forecasted for over $3.5B in combined annual revenue. Neuroscience also outperformed, with Vraylar and the migraine portfolio (Qulipta, Ubrelvy) each posting double-digit gains. Aesthetics returned to positive growth, with international markets offsetting U.S. inflationary softness.
Humira U.S. biosimilar erosion remained modestly better than forecast, primarily driven by volume stability and robust parity access. The company now anticipates 35% erosion for the full year, a two-point improvement versus initial projections. Oncology results were mixed, with Imbruvica down as expected and Venclexta up 15% on strong international uptake. Adjusted operating margin remained robust at 47% of sales, supporting the $1.4B upward revision to full-year revenue guidance, with over 70% of the increase attributed to the growth platform.
- Immunology Growth Surges: Skyrizi global sales up 51%, RINVOQ up 57%, both capturing share in new indications and driving the majority of platform growth.
- Neuroscience Momentum: Vraylar and migraine assets exceeded expectations, with the portfolio on pace to add $1B in incremental revenue for the year.
- Aesthetics International Strength: International aesthetics sales grew nearly 20%, offsetting U.S. market headwinds and stabilizing overall segment performance.
AbbVie’s execution across its five key therapeutic areas exceeded expectations, with volume and access management in Humira and commercial discipline in new launches providing near-term resilience and long-term leverage.
Executive Commentary
"The U.S. Humira biosimilar impact is playing out as projected and slightly better than our planning assumptions. We have exceeded our guidance in both first and second quarters with the overachievement predominantly driven by our growth platform, the base portfolio excluding Humira."
Rick Gonzalez, Chairman and Chief Executive Officer
"We are demonstrating strong execution across our business with each of our five key therapeutic areas beating expectations...With ongoing programs in several additional disease areas, we expect both Skyrizi and RINVOQ to deliver robust growth into the next decade and significantly exceed Humira peak revenue."
Rob Michael, President and Chief Operating Officer
Strategic Positioning
1. Immunology Franchise Transition
Skyrizi and RINVOQ are now the twin pillars of AbbVie’s immunology future. Both drugs are rapidly expanding across multiple indications and have demonstrated head-to-head superiority over legacy therapies. Skyrizi’s in-play prescription share in U.S. psoriasis hit 32%, with 50% capture of new or switching patients, while RINVOQ’s multi-indication strategy is driving rapid uptake in IBD and dermatology. Management expects these assets to surpass Humira’s historical peak revenue, underscoring a successful lifecycle management strategy.
2. Neuroscience as a Growth Engine
The neuroscience portfolio is emerging as a third growth vector, led by Vraylar’s expansion into major depressive disorder and continued leadership in migraine treatments. Qulipta and Ubrelvy both posted >30% growth, and the company raised full-year neuroscience guidance by $300M, reflecting accelerating prescription demand and new approvals on the horizon.
3. Aesthetics Resilience and International Expansion
Allergan Aesthetics remains a global leader, with Botox and Juvederm maintaining strong share despite new entrants. International aesthetics sales, especially in China and Asia-Pacific, have fully recovered to pre-COVID levels, growing nearly 20%. U.S. market softness persisted due to inflation, but leading indicators point to improving consumer intent and procedure volumes into the second half.
4. Oncology Portfolio and Pipeline Progression
Oncology delivered mixed results, with Imbruvica declining but Venclexta and new approvals (Epkinly in DLBCL) supporting the segment. Pipeline progress in hematologic and solid tumors, including Navitoclax and next-generation antibody-drug conjugates, adds to long-term optionality, though near-term revenue contributions remain modest.
5. Capital Allocation and M&A Optionality
AbbVie maintains a disciplined approach to business development, focusing on later-stage assets in core therapeutic areas. Management reiterated that high single-digit growth is achievable without additional M&A, but remains open to bolt-on and transformative deals that meet strategic and return thresholds.
Key Considerations
This quarter marks a turning point in AbbVie’s post-Humira narrative. With biosimilar erosion tracking to plan and the growth platform accelerating, the company is positioned for a rapid return to growth in 2025. Strategic focus remains on maximizing Skyrizi and RINVOQ, leveraging neuroscience momentum, and sustaining aesthetics leadership, while pipeline and external innovation provide medium-term upside.
Key Considerations:
- Humira Erosion Management: Parity access and volume stability have limited downside, with 2024 expected to mark the trough before stabilization in 2025.
- Indication Expansion Strategy: Rapid label growth for Skyrizi and RINVOQ is driving market share gains and de-risking future revenue streams.
- Commercial Execution Discipline: Early access wins and minimized free goods in new launches highlight AbbVie’s payer and provider engagement strength.
- Pipeline Visibility: While near-term growth is concentrated in a few assets, management points to a robust early- and mid-stage pipeline across oncology, neuroscience, and immunology.
- Regulatory and Policy Headwinds: Exposure to IRA (Inflation Reduction Act) is manageable, with only ~20% of U.S. revenue at risk and ongoing modeling of potential impacts.
Risks
Key risks include further Humira price and volume erosion as additional biosimilars gain traction, potential payer pushback on immunology pricing, and concentration risk in Skyrizi and RINVOQ until pipeline diversification matures. Regulatory headwinds from the IRA could affect select products, and macroeconomic conditions may continue to pressure U.S. aesthetics demand. Execution risk remains in pipeline advancement and commercial ramp of new indications.
Forward Outlook
For Q3 2023, AbbVie guided to:
- Net revenues of approximately $13.7B, factoring in ~40% U.S. Humira erosion
- Adjusted EPS between $2.80 and $2.90
For full-year 2023, management raised guidance:
- Total net revenues of approximately $53.4B (up $1B)
- Adjusted EPS of $10.90 to $11.10
Management emphasized continued momentum in the ex-Humira growth platform and expects acceleration in immunology, neuroscience, and aesthetics in the second half. Factors influencing outlook include:
- Further volume and access stability for Humira through 2024
- Ongoing indication launches and formulary wins for Skyrizi and RINVOQ
Takeaways
AbbVie’s Q2 results reinforce the company’s transition to a multi-asset growth platform, with Humira risk largely contained and new franchises scaling rapidly. Investors should monitor the pace of biosimilar adoption, payer dynamics in immunology, and the evolution of the early-stage pipeline for future upside.
- Growth Platform Drives Upside: Ex-Humira assets are delivering above-plan growth, supporting the $1.4B guidance raise and improving visibility to a 2025 inflection.
- Commercial and Pipeline Execution Remain Critical: Success in new launches, indication expansions, and payer contracting will determine the sustainability of the growth narrative.
- Watch for Pipeline Readouts and M&A Activity: Near-term data and potential business development could further diversify the revenue base and de-risk long-term targets.
Conclusion
AbbVie’s Q2 2023 results mark a successful navigation of its most challenging transition period, with the growth platform now outshining Humira and a diversified pipeline supporting long-term ambitions. Execution in immunology, neuroscience, and aesthetics provides resilience, while management’s discipline in capital allocation and pipeline advancement positions the company for sustained outperformance.
Industry Read-Through
AbbVie’s experience with biosimilar erosion and rapid pivot to new growth engines offers a roadmap for other large-cap biopharma facing patent cliffs. The company’s ability to negotiate parity access, execute multi-indication launches, and maintain pricing discipline in immunology sets a high bar for operational agility. The resilience of international aesthetics and the expansion of neuroscience franchises highlight the value of diversified revenue streams. Ongoing IRA uncertainty and payer scrutiny are sector-wide headwinds, but AbbVie’s performance suggests that portfolio breadth and pipeline velocity are the most effective hedges against patent expiry risk.